Scottish Biopharmaceutical Company MGB Biopharma Secures £4.0m ($6.4m) to Develop New Antibacterial Drug against the Major Global Problem of Antimicrobial Resistance

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has secured £4.0m ($6.4m) to advance the development of its lead antibacterial, MGB-BP-3, against a range of Gram-positive infections including Clostridium difficile and methicillin-resistant and susceptible Staphylococcus species. MGB-BP-3 is the first novel class of antibacterial for over a decade with a new mode of action to be developed globally. The drug - originally developed at the University of Strathclyde and licensed to MGB Biopharma - could make a real difference in the fight against antimicrobial resistance.

Project will advance renewable infrastructure in Scotland

The restaurant and nightlife guide plans to invest $1 million over the next year to strengthen its presence in the region

Independent energy company SmartestEnergy is expanding its operations in Scotland on the back of continued growth north of the border.

A new guide to doing business in West Africa launched as Scotland strengthens ties with Commonwealth nations

Companies helped to expand - projected international sales of £1.2 billion

FM address CG2014: 7,446 International jobs boost in 2013/14

Doosan Babcock to create nearly 400 jobs with new Process Engineering Centre in Renfrew.

FM welcomes potential for more than £5 billion Chinese investment